Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy
暂无分享,去创建一个
Fang Wang | Chang Xu | Q. Zhuang | A. Gu | Xiaosong Zhong | Ying Zhang | Can Zhang | William H. Zhong | Yi-lu Hu | William Zhong
[1] J. Kochenderfer,et al. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains , 2021, Nature Reviews Clinical Oncology.
[2] Q. Qian,et al. Current Progress in CAR-T Cell Therapy for Hematological Malignancies , 2021, Journal of Cancer.
[3] R. Kiessling,et al. Counteracting CAR T cell dysfunction , 2020, Oncogene.
[4] G. Coukos,et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression , 2020, The Journal of experimental medicine.
[5] R. Heller,et al. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models , 2021, Frontiers in Immunology.
[6] C. Turtle,et al. Cytokines in CAR T Cell–Associated Neurotoxicity , 2020, Frontiers in Immunology.
[7] P. Dreger,et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. Marincola,et al. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy , 2020, Journal for ImmunoTherapy of Cancer.
[9] M. Maus,et al. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. , 2020, Annual review of medicine.
[10] L. Kats,et al. IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] B. Sun,et al. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice , 2020, Frontiers in Oncology.
[12] Jiang F Zhong,et al. Recent advances in CAR-T cell engineering , 2020, Journal of Hematology & Oncology.
[13] C. Mackall,et al. The Emerging Landscape of Immune Cell Therapies , 2020, Cell.
[14] A. Ducruet,et al. IL (Interleukin)-15 Bridges Astrocyte-Microglia Crosstalk and Exacerbates Brain Injury Following Intracerebral Hemorrhage , 2020, Stroke.
[15] R. Shaik,et al. Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma , 2020, Cancer Immunology Research.
[16] J. Leroux,et al. Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation , 2019, Scientific Reports.
[17] Alaina Kaiser,et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.
[18] E. Sherwood,et al. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. , 2017, Cytokine & growth factor reviews.
[19] Hao Liu,et al. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants , 2017, Cancer Immunology Research.
[20] J. Friedberg,et al. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Schunkert,et al. Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis. , 2017, Cell metabolism.
[22] L. Hurton,et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.
[23] B. Levine,et al. Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.
[24] J. Kochenderfer,et al. Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.
[25] D. Pardoll,et al. Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model , 2016, International journal of cancer.
[26] Julián Pardo,et al. How Do Cytotoxic Lymphocytes Kill Cancer Cells? , 2015, Clinical Cancer Research.
[27] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Schmitt-Graeff,et al. Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. , 2015, Blood.
[29] T. Waldmann,et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Creighton,et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.
[31] H. Wong,et al. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity , 2013, Oncoimmunology.
[32] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[33] J. Prieto,et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. , 2013, Cancer research.
[34] H. Staats,et al. Cytokines: The Future of Intranasal Vaccine Adjuvants , 2011, Clinical & developmental immunology.
[35] F. Marincola,et al. A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.
[36] J. Gołąb,et al. Interleukin 15 as a promising candidate for tumor immunotherapy. , 2011, Cytokine & growth factor reviews.
[37] A. Bessard,et al. High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer , 2009, Molecular Cancer Therapeutics.
[38] Chien-Fu Hung,et al. Expression of IL‐15RA or an IL‐15/IL‐15RA fusion on CD8+ T cells modifies adoptively transferred T‐cell function in cis , 2009, European journal of immunology.
[39] T. Waldmann,et al. Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action1 , 2008, The Journal of Immunology.
[40] T. Waldmann,et al. The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.
[41] J. Sprent,et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[42] L. Park,et al. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex , 1996, Journal of Clinical Immunology.
[43] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[44] P. Burkett,et al. Regulation of lymphoid homeostasis by interleukin-15. , 2002, Cytokine & growth factor reviews.
[45] D. Busch,et al. Overexpression of IL-15 In Vivo Increases Antigen-Driven Memory CD8+ T Cells Following a Microbe Exposure1 , 2002, The Journal of Immunology.
[46] C. Seager. Therapies , 1973, Journal of the Neurological Sciences.
[47] Kirk W. Johnson,et al. The Circulating Common Gamma Chain (CD132) in Inflammatory Bowel Disease , 1998, American Journal of Gastroenterology.
[48] D. Cosman,et al. Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, The EMBO journal.
[49] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.